These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8823262)

  • 21. Selective postoperative radioactive iodine treatment of thyroid carcinoma.
    McHenry C; Jarosz H; Davis M; Barbato AL; Lawrence AM; Paloyan E
    Surgery; 1989 Dec; 106(6):956-8; discussion 958-9. PubMed ID: 2588122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
    Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
    Randolph GW; Daniels GH
    Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
    Mazzaferri EL; Jhiang SM
    Am J Med; 1994 Nov; 97(5):418-28. PubMed ID: 7977430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of the efficacy of iodine-131 for thyroid ablation.
    Comtois R; Thériault C; Del Vecchio P
    J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay.
    Hodgson DC; Brierley JD; Tsang RW; Panzarella T
    Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid cancer in children and adolescents.
    Fassina AS; Rupolo M; Pelizzo MR; Casara D
    Tumori; 1994 Aug; 80(4):257-62. PubMed ID: 7974795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
    Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
    Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of preoperative radioactive iodine (131I) therapy for locally advanced papillary thyroid cancer: a case report.
    Shingu K; Kobayashi S; Yokoyama S; Shimizu T; Kasuga Y; Fujimori M; Ito K; Hama Y; Amano J
    Thyroid; 1998 Dec; 8(12):1113-6. PubMed ID: 9920366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the role of 1100 MBq (< 30 mCi) radioiodine 131I in the treatment of patients with differentiated thyroid cancer?
    van Wyngaarden M; McDougall IR
    Nucl Med Commun; 1996 Mar; 17(3):199-207. PubMed ID: 8692486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on management of differentiated thyroid carcinoma.
    Chopra IJ
    Thyroidology; 1993 Aug; 5(2):57-60. PubMed ID: 7522532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
    Logue JP; Tsang RW; Brierley JD; Simpson WJ
    Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
    Baranauskas ZL; Mamontov VV; Valutskas KK
    Med Radiol (Mosk); 1989 Oct; 34(10):31-4. PubMed ID: 2811625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.